Current medical therapies for epilepsy are anti seizure rather than antiepilepsy medications; that is, they address the symptoms rather than the epileptogenic process. Numerous trials of treatments aiming to interrupt epilepto genesis have been carried out among indivi duals with conditions such as traumatic brain injury, subarachnoid haemorrhage, stroke and neo plasms 1 . The modest success of these trials was mostly in the prevention of acute seizures, with no impact on the later development of epilepsy. The failure to demonstrate an effect on epileptogenesis was potentially attribu table to failures in trial design, including timing and duration of the intervention and a lack of effective biomarkers of epileptogenesis 1, 2 . Another important consideration is that most of the trialled agents were developed as anti seizure medications, and the mechanisms of epilepto genesis may be quite different from those underlying the generation of an individual epileptic seizure 2 . An indirect method to determine success in interrupting epileptogenesis, beyond ani mal models and clinical trials, is to examine temporal trends in the incidence of newonset epilepsy. A number of such studies have been conducted, mostly reporting on regional pop ulations, for example, in South East England, the Midwestern United States, and Northern Sweden 3 . Major efforts in Scandinavia have succeeded in longitudinally monitoring epi lepsy incidence at the national level 4, 5 . These studies examined changes in incidence over children and young adults, but increased fivefold among individuals aged ≥65 years. In addition, the incidence of generalized epilepsy was stable over time, whereas the incidence of focal epilepsy increased. The authors conclude that "no progress has been made in preventing newonset epilepsy" (REF. 6 ).
Though admirable, this study has limita tions. As the investigators readily concede, case ascertainment accuracy was not validated and, therefore, the degree of misidentification of individuals with newonset epilepsy, as well as focal versus generalized epilepsy, remains unknown. The investigators describe the Finnish practice of early referral to hospital for evaluation after a first seizure, and they acknowledge that the absence of primary care data could have as much as halved the recorded number of newonset epilepsies. Moreover, at least some of the temporal trends observed might have been due to changes in referral pat terns rather than changes in incidence at the general population level. The denominator of 5.04 million individuals used in the incidence estimation does not reflect the general Finnish population but, rather, those admitted to hos pital during the study period, further empha sizing the potential difficulty in applying these findings to the general population.
The lack of inferential statistics (for exam ple, tests of significance with Pvalues, or 95% confidence intervals) further complicates our ability to understand which -if any -of the observed changes are important. Such statis tics might also have helped us to understand the relevance of what may be Ushaped trend lines in a number of the subgroup analyses. It would have been interesting to control for age, changes in the distribution of which, as the investigators demonstrate, have important effects on the incidence of epilepsy.
We fully agree with Sillanpää and collabo rators that the medical community continues to struggle to decrease the risk of newonset epilepsy. As mentioned by the investigators, however, the increase in incidence among older individuals should not be interpreted simply as the result of our failure to prevent epileptogenesis -this phenomenon could also reflect both our success and failure to manage the comorbidities of epilepsy. The comorbid ities of epilepsy encompass conditions that occur as a result of epilepsy and those that may act as the primary cause. The prevalence periods spanning from one to several dec ades, largely between the 1970s and early 2000s, and relied on various methods of study design and case ascertainment. The overall temporal trend, which could still be subject to systematic bias, was for a stable or mildly decreasing incidence of newonset epilepsy over time, with some studies reporting a decrease in incidence among children that was balanced to varying degrees by an increase among older adults [3] [4] [5] .
In an elegant study recently published in JAMA Neurology, Sillanpää and collaborators 6 reported on longitudinal patterns in the incidence of newonset epilepsy, based on an administrative, nationwide Finnish cohort. The study used the Finnish Hospital Discharge Register, which monitored 5.04 mil lion indivi duals between 1973 and 2013 -a remarkable 40year followup period. The investigators identified 100,792 individuals with a first hospital admission for epilepsy, and reported an overall incidence of 50 cases per 100,000 personyears. The incidence was stable over the 40year followup period among E P I L E P S Y Trends in new-onset epilepsythe importance of comorbidities
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A recent longitudinal study indicates that the incidence of new-onset epilepsy has remained stable in children and young adults but has increased in elderly individuals over the past 40 years. Rather than signalling a failure to prevent epilepsy, however, this phenomenon might be attributable to the comorbidities of epilepsy. the medical community continues to struggle to decrease the risk of new-onset epilepsy of several comorbidities has increased consid erably over the past few decades 7 , in particu lar, cerebro vascular and neurodegenerative disease, which are the most important risk factors for epilepsy in elderly individuals 8 . The reported increase in focal epilepsy might reflect both a change in the prevalence of these comorbid ities and increased survival of indivi duals with severe disease, who are invariably at higher risk of subsequently developing epilepsy. The decreased incidence in children could be a sign of our success in managing prenatal, perinatal and early childhood risk factors for epilepsy 9 .
Important questions remain regarding temporal trends in epilepsy. Future efforts should be aimed at developing estimates that are representative of the general population, while minimizing the risk of mis identification of newonset epilepsy. Ideally, in addition to examining the number of new cases, we should understand their character, including aeti ology and severity. Care should be taken not to allow recent changes to the definition of epilepsy 10 to create artificial changes in the incidence of new cases. It is also important to remember that epilepsy is a hetero geneous symptom complex rather than a disease in its own right, and the failure to take this fact into account contributes substantially to the mis reading of epidemiological data. Findings such as those presented by Sillanpää and collabora tors should not only inspire us to explore bet ter ways to prevent epilepto genesis, but should also encourage us to double our efforts to prevent the comorbidities that are ultimately responsible for the development of many cases of epilepsy. 
